Current/Future Events - Event View

This is the "Event Detail" view, showing all available information for this event. If the event has passed, click the "Event Report" button to read a report and view photos that were uploaded.

Return to Grid View Show Search

Today

WEBINAR - Next-generation Tech for Early Drug Discovery

When:

Thursday, May 20, 2021, 8:00 AM until 10:00 AM

Where:

Link will be emailed to attendees 2 days prior to the meeting, or the night prior if
registering closer to the event

Event Contact(s):

ORCA Admin

Category:

Webinar

Registration is closed

RSVP by 6:00PM, Wednesday, May 19, 2021

Meetings and webinars are scheduled on Pacific Standard Time or Pacific Daylight Time, whichever applies.

Please make sure that the following email address is in your Safe Sender list: mailer@mail2.clubexpress.com. System messages like meeting announcements, registration confirmations, webinar login instructions as well as certificates of attendance are sent directly from this email address.

You will receive an email 2 days prior to the meeting date with the webinar login instructions or the night prior to the meeting, if registering closer to the meeting date. If you don't receive the instructions within this time frame, please contact us at info@orcanw.org as soon as possible.

PAID FEES ARE NON REFUNDABLE.

For webinar events, payment is REQUIRED at the time of registration.

Capacity:

100

Active Member (Regular, Student, Government)

No Fee

Non-Member

$60.00

Add to my Calendar

The link to the webinar is intended for the registered person ONLY and should not be shared.
All attendees MUST be registered.
This webinar will be recorded.

TOPIC: Next-generation Tech for Early Drug Discovery

TOPIC DESCRIPTION: Antibody therapeutics are one of the fastest growing classes of drugs, addressing critical needs across many diseases. An array of exciting technologies and platforms have emerged to address the growing need for efficacious antibody-based drugs. The newest technologies sit at the intersection of scientific and engineering disciplines including microfluidics, genomics, proteomics, and bioinformatics. This meeting will give an overview of early antibody discovery technology, and exciting developments in response to the COVID-19 pandemic.

SPEAKER: Natalie Castellana

SPEAKER BIOGRAPHY: Natalie Castellana is the CEO of Digital Proteomics LLC. She has led the development of innovative antibody discovery and sequencing technologies at Digital Proteomics since 2012. She received her PhD in Computer Science working with Dr. Vineet Bafna at the University of California - San Diego, and a B.S. in Computer Science from Carnegie Mellon University. Her graduate research focused on methods for integrating genomics and proteomics data to improve genome annotation and antibody sequencing.

Dr. Castellana collaborated with biotechnology company Genentech to release GenoMS, an automated method for sequencing monoclonal antibodies using mass spectrometry. The methods employed by GenoMS form a foundation for the Digital Proteomics service, Valens. Valens is a progenitor of the Alicanto platform, and solves a simpler problem of sequencing a single antibody as opposed to a complex mixture of antibodies from a patient sample.

Dr. Castellana is co-author on 8 peer-reviewed publications in the space of genomic and proteomic data analysis, particularly the area of antibody sequencing. She has given talks and poster presentations at numerous conferences, and co-authored a book chapter on antibody sequencing edited by scientists at Genentech.

https://www.linkedin.com/in/natalie-castellana/
https://www.digitalproteomics.com/

WHO: Clinical, regulatory, quality, manufacturing and legal

Attendance at this meeting may be applied as 1.5 points towards RAC re-certification